Newsroom

Healthcare Pharmaceutical Biotech

Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom. Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place. Whether it’s innovation, regulatory changes, or breakthroughs, our newsroom keeps you connected to the stories that matter most.


Latest Press Releases

The End of
Healthcare & PharmaceuticalCompany Update

The End of "What's for Dinner?" - MDCE Launches AI App That Thinks Like a Chef! Download Snapshot Recipes Today!

February 27, 2026 9:11 AM

Medical Care Technologies, Inc. (OTC PINK:MDCE) today announced the official launch of its first consumer-based artificial intelligence mobile application, Snapshot Recipes, now available on both the Apple iOS App Store and the Google Play Store. Users can learn more and download the app at: www.snapshotrecipes.app Snapshot Recipes leverages advanced artificial intelligence to revolutionize how consumers prepare meals. The app allows users to:...

Read more
ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States
Healthcare & PharmaceuticalConferences

ZetrOZ Systems Extends Its Non-Invasive Knee Osteoarthritis Treatment to Orthopaedic Surgeons Across the United States

February 27, 2026 9:05 AM

ZetrOZ Systems will showcase its sam® sustained acoustic medicine technology's effectiveness in treating knee osteoarthritis and other musculoskeletal conditions at the annual meeting of the American Academy of Orthopaedic Surgeons, March 3-5, in New Orleans. The company will provide clinical information and demonstrate the sam® wearable ultrasound device at Booth 3612 in Hall E of the Ernest N. Morial Convention Center. ZetrOZ Systems also is...

Read more
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Healthcare & PharmaceuticalCompany Update

European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

February 27, 2026 7:00 AM

Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union for mCOMBRIAX® (mRNA-1083), Moderna's combination vaccine indicated for active immunization for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. "The CHMP's...

Read more
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Healthcare & PharmaceuticalRegulatory

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

February 27, 2026 3:23 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 27 February 2026 consists of6,425,429ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 6,425,429. The figure of 6,425,429 ordinary shares may be used by shareholders of the...

Read more
Vanish DrySerum Review 2026: Don't Buy This Nanofiber Acne Mask Without Reading This First!
Healthcare & PharmaceuticalAdvertorial

Vanish DrySerum Review 2026: Don't Buy This Nanofiber Acne Mask Without Reading This First!

February 26, 2026 10:40 PM

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new skincare product. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. Vanish DrySerum 2026: Consumer...

Read more
BioNxt Announces Closing of Shares for Debt Settlement
Healthcare & PharmaceuticalCompany Update

BioNxt Announces Closing of Shares for Debt Settlement

February 26, 2026 7:00 PM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated January 23, 2026, the Company has issued an aggregate of 6,008,883 common shares in the capital of the Company (the "Debt Shares") at a deemed price of $0.45 per Debt Share to settle $2,704,000 in debt (the "Debt") owed to certain arm's length creditors (the "Debt Settlement"). The Debt was comprised...

Read more
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Healthcare & PharmaceuticalEarnings

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 26, 2026 4:15 PM

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients Announced agreement with FDA on a single adaptive Phase 2/3...

Read more
NHI Issues Investor Update
Healthcare & PharmaceuticalCompany Update

NHI Issues Investor Update

February 26, 2026 4:10 PM

National Health Investors, Inc. (NYSE:NHI) has issued the following investor update which can be found at: https://investors.nhireit.com/News/presentations-and-webcasts/default.aspx About National Health Investors, Inc. National Health Investors, Inc. (NYSE:NHI), established in 1991 as a Maryland corporation, is a self-managed real estate investment trust ("REIT"). The Company owns, leases, operates and finances the development of high-quality...

Read more
NHI Announces The First Quarter 2026 Dividend
Healthcare & PharmaceuticalDividends

NHI Announces The First Quarter 2026 Dividend

February 26, 2026 4:10 PM

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its first quarter dividend of $0.92 per common share on May 1, 2026, to stockholders of record as of March 31, 2026. About National Health Investors, Inc. National Health Investors, Inc. (NYSE:NHI), established in 1991 as a Maryland corporation, is a self-managed real estate investment trust ("REIT"). The Company owns, leases, operates and finances the development of...

Read more
NHI Announces Fourth Quarter 2025 Results
Healthcare & PharmaceuticalEarnings

NHI Announces Fourth Quarter 2025 Results

February 26, 2026 4:05 PM

National Health Investors, Inc. (NYSE:NHI) announced today its results for the fourth quarter and year ended December 31, 2025. CEO Comments "NHI generated strong financial results in 2025 that exceeded our initial NAREIT FFO, Normalized FFO and FAD guidance," said Eric Mendelsohn, NHI's President and CEO. "We significantly expanded the Senior Housing Operating Portfolio ("SHOP") during 2025 from 15 properties to 26 properties. We recently...

Read more
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Healthcare & PharmaceuticalEarnings

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

February 26, 2026 4:05 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025. "2025 underscored Amphastar's evolution into a company focused on both commercial strength and scientific...

Read more
MD Clarity Named to G2's 2026 Best Software Awards, Ranking in G2's Top 50 Across All Healthcare Software Categories
Healthcare & PharmaceuticalAwards

MD Clarity Named to G2's 2026 Best Software Awards, Ranking in G2's Top 50 Across All Healthcare Software Categories

February 26, 2026 12:00 PM

MD Clarity, a leading provider of revenue optimization solutions, today announced it has been named to G2's 2026 Best Software Awards, earning a spot on G2's 50 Best Healthcare Software Products list. Notably, MD Clarity is one of just two Revenue Cycle Management platforms that made it onto the list. This follows MD Clarity earning two accolades as High Performer and Momentum Leader in G2's Winter 2026 Grid Report. G2's Best Software Awards...

Read more
Dosell Awarded Framework Agreement in Sweden's First National Procurement of Medication Dispensing Systems
Healthcare & PharmaceuticalCompany Update

Dosell Awarded Framework Agreement in Sweden's First National Procurement of Medication Dispensing Systems

February 26, 2026 10:30 AM

iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ) announces that its subsidiary Dosell AB has been awarded a framework agreement in ADDA's national procurement "Medication Dispensing Systems with Remote Care Platform 2025". This marks Sweden's first national procurement of medication dispensing systems and remote care platforms. The framework agreement enables municipalities and regions across Sweden to procure Dosell's solution for safe,...

Read more
DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies
Healthcare & PharmaceuticalEnvironmental, Social and Governance

DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies

February 26, 2026 9:15 AM

DaVita, a leading provider of comprehensive kidney care, has been named to Fortune's World's Most Admired Companies list for the 20th time, marking two decades of sustained recognition for its commitment to culture, innovation, teammate (employee) well‑being and social responsibility. The milestone reflects DaVita's enduring mission-to be the provider, partner and employer of choice-and highlights how a values‑driven culture can power long‑term...

Read more
Are Young Adults Still Smoking? A CVS Health Survey Unveils Striking Insights
Healthcare & PharmaceuticalEnvironmental, Social and Governance

Are Young Adults Still Smoking? A CVS Health Survey Unveils Striking Insights

February 26, 2026 9:00 AM

Originally published on CVS Health Company News By Dr. David Fairchild, SVP and Chief Medical Officer, Retail Health, CVS Health® Key points The work to end tobacco and nicotine use in the U.S. is as important as ever - according to findings from a CVS Health® survey. One third of U.S. young adults use nicotine products, and half don't know how to access cessation programs. As electronic cigarettes (e-cigarettes) continue to gain popularity,...

Read more
Stemtech Corporation Launches New Market Channel Biosciences Ecommerce
Healthcare & PharmaceuticalCompany Update

Stemtech Corporation Launches New Market Channel Biosciences Ecommerce

February 26, 2026 8:30 AM

Stemtech Corporation, the global leader and pioneer in stem cell nutrition, launches Stemtech BioSciences E-Commerce Retail market channel. (Stemtech Corporation - OTCID:STEK) "Live Longer - Live Better - Live Younger" President & COO, John W. Meyer stated "We are pleased to launch our new BioSciences Platform. This new program is a powerful initiative designed to expand our reach and to strengthen and diversify our foundation. BioSciences will...

Read more
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
Healthcare & PharmaceuticalProduct Announcements

CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness

February 26, 2026 8:30 AM

CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced the launch of Empowr, a plant-based protein and creatine powder for everyday adults looking to increase daily protein intake for overall wellness. "Empowr" represents a dynamic evolution in functional nutrition," said Joseph Dowling,...

Read more
Black Book Research Releases
Healthcare & PharmaceuticalProduct Announcements

Black Book Research Releases "France: State of Acute Care EHR and Digital Health 2026"

February 26, 2026 8:15 AM

Black Book Market Research today announced the publication of France: State of Acute Care EHR and Digital Health 2026 a qualitative market report intended to support hospital executives, CIO/DSI leadership, clinical informatics teams, and procurement stakeholders evaluating acute-care DPI/EHR modernization and replacement programs for the 2026-2030 planning horizon. The France edition reviews doctrine-aligned interoperability requirements,...

Read more
Umbrella Labs Announces GLP-3R, The New Research Designation For Retatrutide, To Support High Rigor Tri-Receptor Endocrine Signaling Bench Science
Healthcare & PharmaceuticalCompany Update

Umbrella Labs Announces GLP-3R, The New Research Designation For Retatrutide, To Support High Rigor Tri-Receptor Endocrine Signaling Bench Science

February 26, 2026 7:15 AM

Umbrella Labs today announced an updated research catalog standard that formally presents GLP-3R as the internal research designation for retatrutide, also identified as LY-3437943, supplied as a lyophilized peptide vial for laboratory developmental research use only. This program is designed for laboratories building reproducible tri-receptor signaling studies where naming clarity, lot traceability, and documentation readiness directly impact...

Read more
IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease
Healthcare & PharmaceuticalRegulatory

IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease

February 26, 2026 6:15 AM

IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, today announces that the first patient has been dosed in a Phase Ib study with IRL757 - a potential new treatment for Parkinson's disease-related apathy. This event triggers a USD 3 million milestone payment to IRLAB, payable in instalments in 2026. The study is fully funded by IRLAB's development collaborator,...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?